Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation

Immunologic Research

Volumn 18, Issue 1, 1998, Pages 55-60

  Levy, Yair ^a   George, Jacob ^a   Yona, Eli ^b   Shoenfeld, Yehuda ^a,c  

^a Dept Med B Res U Autoimmune Dis ^*  (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Autoimmune diseases; C3NeF; Complement; Mesangiocapillary glomerulonephritis; Nephritic factor; Partial lypodystrophy; Review

Indexed keywords

AUTOANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G;

AUTOIMMUNE DISEASE; COMPLEMENT DEFICIENCY; COMPLEMENT SYSTEM; LIPODYSTROPHY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PRIORITY JOURNAL; REVIEW;

EID: 0031716120     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02786513     Document Type: Review

References (45)

1. Senior B, Gellis SS. The syndromes of total lipodystrophy and partial lipodystrophy. Pediatrics 1964;33:593-612.
2. Piscatelli RL, Vieweg WVR, Hvel RJ. Partial lipodystrophy:metabolic studies in three patients. Ann Intern Med 1970;73:963-970.
3. Gellis SS, Green S, Walker D. Chronic renal disease in children with lipodystrophy. Am J Dis Child 1958;96:605-611.
4. Eisinger AJ, Shortland JR, Moorhead PJ. Renal disease in partial lipodystrophy. Q J Med 1972;41: 343-354.
5. Hamza M, Levy M, Broyer M, et al. Deux cas de glomerulo-nephrite membrano-proliferative avec lipodystrophie partielle de type facio-tronculaire. J Urol Nephrol (Paris) 1970;76:1032-1042.
6. Peters DK, Charlesworth JA, Sissons JG, Williams DG, Boulton-Jones JM, Evans DJ, et al. Mesangiocapillary nephritis, partial lipodystrophy and hypocomplementaemia. Lancet 1973;2:535-538.
7. Bennett WM, Bardana EJ, Wuepper K, et al. Partial lypodystrophy, C3 nephritic factor and clinically inapparent mesangiocapillary glomerulonephritis. Am J Med 1977; 62:757-760.
8. Alper CA, Bloch KJ, Rosen FS. Increased susceptibility to infection in a patient with type two essential hypercatabolism of C3. N Engl J Med 1973;288:601-606.
9. Vallota EH, Gotza O, Spiegelberg HL, et al. A serum factor in chronic complementemic nephritis distinct from immunoglobulins and activating the alternate pathway of complement. J Exp Med 1974; 139:1249-1261.
10. Ipp MM, Minta JO, Gelfand EW. Disorders of the complement systems in lypodystrophy. Clin Immunobiol Immunopathol 1977; 7:281-287.
11. Spitzer RE, Vallota EH, Forristal J, Sudora E, Stitzel AE, Davis NC. Serum C'3 lytic system in patients with glomerulonephritis. Science 1969;164:436-437.
12. Schreiber RD, Medicus RG, Gotze O, et al. Properdin-and nephritic factor-dependent C3 convertase: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med 1975; 142:760-772.
13. Dana MR, Fearon DT, Austen KF. C3 nephritic factor (C3Nef): stabilization of fluid phase and cell bound alternative pathway convertase. J Immunol 1976;116:1-7.
14. Spitzer RE, Stitzel AE, Tsokos GC. Human anti-idiotypic antibody responses to autoantibody against the alternative pathway C3 converlase. Clin Immunol Immunopathol 1990;57:19-31.
15. Spitzer RE, Stitzel AE, Tsokos GC. Nephritic factor antibodies, in Peter JB, Shoenfeld Y (eds.): Autoantibodies. Elsevier Science, Amsterdam, The Netherlands, 1996, pp. 540-545.
16. Tanuma Y, Ohi H, Hatano M. Two typesof C3 nephritic factor:properdin-dependent C3NeF and properdin-independent C3NeF. Clin Immunol Immunopathol 1990;56:226-238.
17. Finn JE, Mathieson PW. Molecular analysis of C3 allotypes in patients with nephritic factor. Clin Exp Immunol 1993;91:410-414.
18. Sissons JGP, West RJ, Fallows J, Williams DG, Boucher BJ, Amos N, et al. The complement abnormalities of lipodystrophy. N Engl J Med 1976;294:461-465.
19. Rosen BS, Cook KS, Yaglom J, Groves DL, Volanakis D, Damm D, et al. Adipsin and complement factor D activity:an immune-related defect in obesity. Science 1989;244:1483-1487.
20. Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 1992; 267:12,736-12,743.
21. Mathieson PW, Wurzner R, Oliveira DBG, Lachmann PJ, Peters DK. Complement-mediated adiposcyte lysis by nephritic factor. J Exp Med 1993;177:1827-1831.
22. Schena FP, Pertosa G, Stanziale P, Vox E, Pecoraro C, Andreucci VE. Biological significance of the C3 nephritic factor in membrano-proliferative glomerulonephritis. Clin Nephrol 1982;18:240-246.
23. Jackson EC, McAdams AJ, Strife CF, Forristal J, Welch TR, West CD. Differences between membrano-proliferative glomerulonephritis types I and III in clinical presentation, glomerular morphology, and complement perturbation. Am J Kidney Dis 1987;9:115-120.
24. Habib R, Gubler MC, Chantal L, Maiz HB, Levy M. Dense deposit disease: a variant of membrano-proliferative glomerulonephritis. Kidney Int 1975;7:204-215.
25. McLean RH, Siegel NJ, Kashgarian M. Activation of the classic complement pathway in patients with the C3 nephritic factor. Nephron 1980;25:57-64.
26. Marder HK, Coleman TH, Forristal J, Beischel L, West CD. An inherited defect in the C3 convertase C3bBb, associated with glomerulonephritis. Kidney Int 1983;23:749-758.
27. Meri S, Koisteinen V, Miettinen A, Tornroth T, Seppala IJT. Activation of the alternative pathway of complement by monoclonal L light chains in membranopro-liferative glomerulonephritis. J Exp Med 1992;175:939-950.
28. Lopez-Larrea C, Dieguez MA, Enguix A. Dominguez O, Marin B, Gomez E. A familial deficiency of complement factor H. Biochem Soc Trans 1987;15:648-649.
29. Ohi H, Tanuma Y, Hatano M. Is membranoproliferative glomerulonephritis an autoimmune disease? Nephron 1990;54:192
30. Ohi H, Watanabe S, Fujita T, Seki M, Hatano M. Detection of C3bBb -stabilizing activity (C3 nephritic factor) in the serum from patients with membranoprolifirative glomerulonephritis. J Immunol Methods 1990;131:71-76.
31. Tanuma Y, Ohi H , Watanabe S, Seki M, Hatano M. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis. Clin Exp Immunol 1989; 76:82-85.
32. Daha MR, Hazevoet HM, Van Es LA, Cats A. Stabilization of the classical pathway C3 convertase C42 by a factor F-42 isolated from patients with systemic lupus erythematosus. Immunology 1998; 40:417-24.
33. Fujita T, Sumita T, Yoshida S, Ito S, Tamura N. C4 nephritic factor in a patient with chronic glomerulonephritis. J Clin Lab Immunol 1987;22:656-70.
34. Halbwachs L, Leveille M, Lesarre P, Wattel S, Leibowitch I. Nephritic factor of the classical pathway of complement immunoglobulin G autoantibody directed against the classical pathway C3 convertase enzyme. J Clin Invest 1980;65:1249-1256.
35. Ohi H, Yasugi T. Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis. Clin Exp Immunol 1994;95:316-321.
36. West CD. Nephritic factors predispose to chronic glomerulonephritis. Am J Kidney Dis 1994; 24:956-963.
37. Wilson WA, Sissons JGP, Morgan OS. Multiple autoimmune diseases with bilateral optic atrophy and lipodystrophy. Ann Intern Med 1978;89:72-73.
38. Alarcon-Segovia D, Ramos-Niembro F. Association of partial lipodystrophy and Sjogren's syndrome. Ann Intern Med 1976;85: 474,475.
39. Font J, Herrero C, Bosch X, Cervera R, Ingelmo M, Mascaro JM. Systemic lupus erythematosus in a patient with partial lipodystrophy. J Am Acad Dermatol 1990;22:337-340.
40. Jasin HE. Systemic lupus erythematosus, partial lipodystrophy and hypocomplementemia. J Rheumatol 1979;6:43-46.
41. Walport MJ, Davies KA, Botto M, Naughton MA, Isenberg DA, Biasi D, et al. C3 nephritic factor and SLE:report of four cases and review of the literature. Q J Med 1994;87:609-615.
42. Cronin CC, Higgins T, Molloy M. Lupus, C3 nephritic factor and partial lypodystrophy. Q J Med 1995;88:298-299.
43. Morgan BP, Walport MJ. Complement deficiency and disease. Immunol Today 1991;12:301-306.
44. Bacchi VF, Maillet F, Berlan L, Kazatchkine MD. Neutralising antibodies against C3NeF in intravenous immunoglobulin. Lancet 1992;340:63-64.
45. Levy Y, George J, Yona E, Shoenfeld Y. Partial lypodystrophy and complement dysfunction. Turk J Immunol 1996;2: 43-45.